Research News
View articles by month and year
-
Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
Early results suggest that a combination of four medicines given BEFORE surgery to treat HER2-positive, early-stage breast cancer may be a good way to weaken and destroy breast cancer cells.
-
Herceptin May Help Treat Small, Early-Stage HER2-Positive Breast Cancers
Research suggests that Herceptin may be able to reduce the risk of recurrence of early-stage, HER2-positive breast cancers that are smaller than 1 cm and haven't spread to the lymph nodes.
-
Experimental Medicine May Help Treat Advanced-Stage Breast Cancer
A small study suggests that an experimental targeted therapy may be able to treat a variety of advanced-stage cancers (including breast) that have stopped responding to standard treatments.
-
Experimental Iniparib Plus Chemo Can Help Treat Metastatic, Triple-Negative Disease
A small study found that iniparib -- one of several new, experimental medicines called PARP inhibitors -- improved survival when combined with chemotherapy to treat metastatic, triple-negative breast cancer.
-
Herceptin Effectiveness Not Affected by Obesity
A small study found that Herceptin worked equally well in obese and non-obese women diagnosed with HER2-positive, metastatic breast cancer.
-
Herceptin Works Well in Older Women Diagnosed with HER2-Positive, Metastatic Disease
A small study suggests that older women diagnosed with HER2-positive, metastatic breast cancer can benefit from Herceptin treatment.
-
Experimental T-DM1 May Help Treat Metastatic, HER2-Positive Disease
A small, early study suggests that T-DM1, an experimental medicine, may be a better first treatment for women diagnosed with metastatic, HER2-positive breast cancer than a combination of Herceptin and Taxotere.
-
Herceptin-Avastin-Taxotere Combo Can Help Treat Metastatic HER2-Positive Breast Cancer
A small, very early study found that about 78% of women diagnosed with metastatic, HER2-positive breast cancer got some benefit from a combination of Herceptin, Avastin, and Taxotere as a first treatment.
-
FDA Turns Down Accelerated Approval Request for T-DM1
The FDA has decided to not consider accelerated approval for T-DM1 to treat HER2-positive, advanced-stage breast cancer based on research results available as of August 2010.
-
Expert Panel Votes Against Continuing Approval for Avastin to Treat Metastatic Breast Cancer
A panel of experts voted against continuing the approval of Avastin in combination with Taxol to treat metastatic, HER2-negative breast cancer and also voted unanimously against approving Avastin in combination with other chemotherapy medicines to treat metastatic breast cancer.
